Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
Barrios CH, Blackstein ME, Blay JY, Casali PG, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P. Barrios CH, et al. Among authors: purkayastha d. Eur J Cancer. 2015 Nov;51(16):2423-33. doi: 10.1016/j.ejca.2015.07.010. Epub 2015 Aug 3. Eur J Cancer. 2015. PMID: 26248685 Free article.
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Hughes TP, et al. Among authors: purkayastha d. Blood. 2014 Jul 31;124(5):729-36. doi: 10.1182/blood-2013-12-544015. Epub 2014 Jun 19. Blood. 2014. PMID: 24948656 Free article. Clinical Trial.
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP. Raut CP, et al. Among authors: purkayastha dd. JAMA Oncol. 2018 Dec 1;4(12):e184060. doi: 10.1001/jamaoncol.2018.4060. Epub 2018 Dec 13. JAMA Oncol. 2018. PMID: 30383140 Free PMC article. Clinical Trial.
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, Rowley SD, Kim DDH, Hernandez D, Rajkhowa T, Haines K, Bonifacio G, Rine P, Purkayastha D, Fernandez HF. Maziarz RT, et al. Among authors: purkayastha d. Bone Marrow Transplant. 2021 May;56(5):1180-1189. doi: 10.1038/s41409-020-01153-1. Epub 2020 Dec 7. Bone Marrow Transplant. 2021. PMID: 33288862 Free PMC article. Clinical Trial.
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Yardley DA, Hart L, Favret A, Blau S, Diab S, Richards D, Sparano J, Beck JT, Richards P, Ward P, Ramaswamy B, Tsai M, Blackwell K, Pluard T, Tolaney SM, Esteva FJ, Truica CI, Alemany C, Volas-Redd G, Shtivelband M, Purkayastha D, Dalal AA, Miller M, Hortobagyi GN. Yardley DA, et al. Among authors: purkayastha d. Clin Breast Cancer. 2019 Aug;19(4):268-277.e1. doi: 10.1016/j.clbc.2019.02.007. Epub 2019 Feb 28. Clin Breast Cancer. 2019. PMID: 31160171 Clinical Trial.
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. Bardia A, et al. Among authors: purkayastha d. Clin Cancer Res. 2021 Aug 1;27(15):4177-4185. doi: 10.1158/1078-0432.CCR-20-2114. Epub 2021 Mar 15. Clin Cancer Res. 2021. PMID: 33722897 Free PMC article. Clinical Trial.
90 results